Relief Therapeutics Holding AG (RLFTF)

[changes_iv]

This is awesome - analysis supporting EUA immediately. "Our findings regarding IL-6 contributions to COVID-related death are consistent with an increasing body of data demonstrating correlation between IL-6 levels and outcome.23 The importance of IL-6 in the pathophysiology of respiratory demise from COVID is further highlighted by the recent Emergency Use Authorization for the IL-6 receptor antagonist tociluzimab (Actemra®, Genentech). Clinical data in support of tociluzimab come from the RECOVERY trial, which showed higher 28-day survival rates (35% vs. 31%) in patients assigned to tociluzimab vs. placebo and the EMPACTA, which showed increased 28-day success rates of 88.0 vs. 80.7%.
Tociluzimab and other IL-6 receptor antagonists block the downstream effects of IL-6 elevation. However, they do not modify the inflammatory processes leading to elevations in IL-6. For example, in one study of IL-6 prior to and following tociluzimab, median IL-6 levels increased, rather than decreased, following treatment, with levels of increase predicting subsequent treatment failure.24 Here, Aviptadil treatment stabilized IL-6 levels leading to increased survival. The relationship between IL-6 and outcome further suggests that it may prove useful in “real time” during treatment to help further optimize Aviptadil dosing across subjects." ~ from Glunker, Y@h00 RLFTF finance conversations